前收市價 | 8.54 |
開市 | 8.52 |
買盤 | 8.88 x 100 |
賣出價 | 9.03 x 100 |
今日波幅 | 8.41 - 9.07 |
52 週波幅 | 1.81 - 15.05 |
成交量 | |
平均成交量 | 266,730 |
市值 | 339.057M |
Beta 值 (5 年,每月) | 1.94 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -4.83 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 17.00 |
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]